2020.4.22, according to CDE website , NMPA accepted the IND of CDK4/6 Inhibitor XH-30002 from Shanghai Xunhe Pharma (上海勋和医药), held a pre-IND meeting with NMPA on Dec 2019. According to the official websites, Shanghai Xunhe Pharma focused on innovation in oncology, cardiovascular, respiratory and mental disease, targeting PARP, JAK2, BET, CDK. Shanghai Xunhe Pharma completed its first round tens of millions financing in 2018.
Popular posts from this blog
Guideline on the Submission of Clinical Trial Data (Draft for Public Review) Center for Drug Evaluation, NMPA May, 2020 Table of Contents 1. Background and Purposes 3 2. Submission Components of Clinical Trial Data 4 2.1 Study database 4 2.2 Analysis database 5 2.3 Data Definition File 6 2.4 Annotated CRF 7 2.5 Programming Code 7 3. Submission Document Format and Conventions 8 3.1 Portable document format 8 3.2 Extensible mark-up language format 8 3.3 Plain text format 8 3.4 Data transport file format 8 3.5 Dataset split 9 3.6 Dataset name, variable name and length 9 3.7 Dataset labels and variable labels 10 4. Other Considerations 10 4.1 Traceability of trial data 10 4.2 Data files under eCTD 11 4.3 Foreign language database 11 4.4 Communication with regulatory agency 11 References 11 Guideline on the Submission of Clinical Trial Data 1. Background and Purposes Clinical trial data is one of the important mate
Belows are the drug review package of Chinese new chemical or biologic drug: Benaglutide (贝那鲁肽, HYBR-014, GLP-1) was developed by Benemae Pharma (filing for STAR), approved in 2016/12/19, click here . Anlotinib (安罗替尼, AL3818, VEGFR/FGFR/PDGFR) was developed by Chia Tai Tianqing Pharma (HK: 01177), approved in 2018/5/9, click here . Mecapegfilgrastim (硫培非格司亭, 19K, G-CSF) was developed by Hengrui Medicine (SH: 600276), approved in 2018/5/18, click here . Fruquintinib (呋喹替尼, HMPL-013, VEGFR) was developed by Hutchison MediPharma (NASDAQ: HCM), approved in 2018/9/5, click here . Toripalimab (特瑞普利单抗, JS001, PD-1) was developed by Junshi Biosciences (HK: 01877/filing for STAR), approved in 2018/12/17, click here . Sintilimab (信迪利单抗, IBI308, PD-1) was developed by Innovent Biologics (HK: 01801), approved in 2018/12/27, click here . Camrelizumab (卡瑞利珠单抗, SHR1210, PD-1) was developed by Hengrui Medicine (SH: 600276), approved in 2019/5/5, click here . Loxenatide (洛塞那